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,e purpose of this study is to evaluate the feasibility of extending a previously developed amyloid biomathematical screening
methodology to support the screening of tau radiotracers during compound development. 22 tau-related PET radiotracers were
investigated. For each radiotracer, in silico MLogP, Vx, and in vitro KD were input into the model to predict the in vivo K1, k2, and
BPND under healthy control (HC), mild cognitive impaired (MCI), and Alzheimer’s disease (AD) conditions. ,ese kinetic
parameters were used to simulate the time activity curves (TACs) in the target regions of HC,MCI, and AD and a reference region.
Standardized uptake value ratios (SUVR) were determined from the integrated area under the TACs of the target region over the
reference region within a default time window of 90–110min. ,e predicted K1, k2, and BPND values were compared with the
clinically observed values. ,e TACs and SUVR distributions were also simulated with population variations and noise. Finally,
the clinical usefulness index (CUI) ranking was compared with clinical comparison results. ,e TACs and SUVR distributions
differed for tau radiotracers with lower tau selectivity.,e CUI values ranged from 0.0 to 16.2, with 6 out of 9 clinically applied tau
radiotracers having CUI values higher than the recommend CUI value of 3.0. ,e differences between the clinically observed
TACs and SUVR results showed that the evaluation of the clinical usefulness of tau radiotracer based on single target binding
could not fully reflect in vivo tau binding.,e screening methodology requires further study to improve the accuracy of screening
tau radiotracers. However, the higher CUI rankings of clinically applied tau radiotracers with higher signal-to-noise ratio
supported the use of the screening methodology in radiotracer development by allowing comparison of candidate radiotracers
with clinically applied radiotracers based on SUVR, with respect to binding to a single target.
1. Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder defined by histopathological features such as senile
plaques and neurofibrillary tangles (NFT), and clinical
symptoms such as memory loss and reduced executive
functions [1]. ,e yearly number of AD cases is increasing
worldwide, leading to an increased cost of care for dementia
patients. Positron emission tomography (PET) using amy-
loid and tau radiotracers can measure the amyloid and tau
loads, in terms of standardized uptake values ratio (SUVR),
and their distributions in a subject’s brain from static PET
images. Since abnormal accumulation of amyloid and tau in
the brain occurs before clinical symptoms appear, the im-
aging of these precursors can support differential diagnosis
and early intervention to increase the success rate of treating
AD or slow down the rate of dementia. As such, the 2018
National Institute on Aging-Alzheimer’s Association (NIA-
AA) research framework includes not only symptomatic
stages of AD, but also biomarker classification involving
amyloid, tau, and neurodegeneration AT(N) biomarkers [2].
,e new framework will be able to identify subjects at risk
for AD for suitable and early treatment, in particular,
preclinical AD subjects (classified as A+T−(N−) or
A+T+(N+)), who are not cognitively impaired but have
abnormal amyloid and tau protein deposits [2].
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Despite active efforts since 2000 to develop amyloid and
tau-targeting PET radiotracers to assist in the diagnosis of
AD and to support AD drug development, there are few
radiotracers that have made it into clinical studies and
displayed good clinical efficacy. In conventional radiotracer
and drug development, poor bench-to-bedside translation
often results due to the differences between in vitro and in
vivo conditions. Similarly, animal models, especially ro-
dents, are often poor predictors of human physiology and
treatment response and have been reported to be incorrect in
approximately one out of three cases [3]. Although larger
animals (e.g., pigs and primates) show closer physiology to
that of human, they are still in-prefect human models and
are costly for high-throughput screening compared to ro-
dents. ,ese issues lead to high attrition rates in drug and
radiotracer development. Biomathematical simulation can
complement high-throughput screening by allowing si-
multaneous and rapid evaluation of many candidate ra-
diotracers [4–6].
Compared to amyloid radiotracers, the development of a
successful tau radiotracer encounters additional challenges
due to the tau phenotypes. Tau proteins have six isoforms,
which differ in the number of exons (0, 1, 2) on the acidic
region and the number of repeats (3 repeats (3R) or 4R) in
the repeat-domain regions [7]. ,e different isoforms un-
dergo several posttranslational modifications, leading to
various ultrastructural conformations, which will affect the
binding of tau radiotracers. In addition, they also need to
discriminate between the paired helical filament (PHF) tau
from other β-sheet structured aggregates such as amyloid-
beta (Aβ) and α-synuclein. Although the tau protein is larger
than the Aβ protein, the tau binding sites are present in
smaller concentrations compared to the Aβ binding sites by
5–20 folds; hence, the selectivity of tau over other β-sheet
structured aggregates needs to be high to ensure accurate
quantification. Moreover, as tau proteins exist in-
tracellularly, tau radiotracers not only need to cross the
blood-brain barrier (BBB), they also need to be able to cross
the cell membrane [8].
Existing clinically applied tau radiotracers showed some
limitations. [11C]PBB3 has high binding selectivity to tau
over Aβ, but it is difficult to synthesize as it will undergo
photoisomerization [9]. Moreover, it is rapidly metabolized
in the plasma, and its polar metabolite is shown to cross the
blood-brain barrier and enter into the brain [10]. ,e short
half-life of carbon-11 has also prompted the development of
fluorinated PBB3 compounds ([18F]AM-PBB3 and [18F]PM-
PBB3) and other tau radiotracers so that they can be used in
hospitals without dedicated cyclotron facilities. [18F]T808
(also known as [18F]AV-680) exhibits defluorination, which
will affect the quantitative analysis of PET images especially
for regions near the skull [11]. Some THK compounds
(Tohoku University, Japan) showed differences in the uptake
due to the enantiomeric properties of the compounds [12]. A
serious confounding factor facing the development of tau
radiotracers is off-target brain binding, which might affect
the quantitative analysis of the PET images as observed in
[11C]PBB3, [18F]THK5351, and [18F]flortaucipir (also
known as [18F]AV1451 or [18F]T807) [13–15]. [18F]MK6240
was reported to have reduced off-target binding but further
evaluation was still required [16].
We have previously developed an amyloid bio-
mathematical screening methodology to support the screen-
ing of candidate amyloid radiotracers during compound
development [4, 5]. ,e screening methodology predicts the
standardized uptake values ratios (SUVRs) of different subject
conditions of a radiotracer and then compares the clinical
usefulness of multiple radiotracers simultaneously in dis-
criminating the subject conditions using a clinical usefulness
index (CUI). ,e CUI was developed to objectively evaluate
the clinical usefulness of a radiotracer, based on its binding
capability to a single target of interest, in terms of SUVR. ,e
SUVR is a semiquantitative parameter that generalizes the
complicated behaviors of tau radiotracers. SUVR is also
generally preferred for diagnosis of patients in amyloid and
tau imaging; hence, the clinical data are more readily available
for comparison. ,us, we chose SUVR over other kinetic
parameters such as nondisplaceable binding potential (BPND,
unitless).
In this study, we evaluate the feasibility of extending the
amyloid-validated screening methodology to support the
development of tau PET radiotracers, where more challenges
like off-target binding exist. ,is is the first in silico method
investigated, which uses the physicochemical and pharma-
cological properties of the compounds to support tau PET
radiotracers developments. 22 PET radiotracers reported to
bind to tau proteins were investigated, including 9 clinically
applied and tau-focused radiotracers, namely, [18F]THK523,
[18F]THK5105, [18F]THK5117, [18F]THK5317, [18F]THK5351,
[18F]flortaucipir, [18F]T808, [11C]PBB3 and [18F]MK6240, and
3 clinically applied but non-tau-focused radiotracers, specif-
ically [18F]Lansoprazole, [11C]Astemizole, and [18F]FDDNP.
2. Materials and Methods
An overview of the amyloid biomathematical methodology
is described briefly, followed by the screening of tau PET
radiotracers using the biomathematical methodology. ,e
details of the methodology are found in somewhere [4, 5].
2.1. Biomathematical Screening Methodology. ,e screening
methodology was based on a simplified 1-tissue-
compartment model (1TCM), with the assumption that
the radiotracers cross the blood-brain barrier (BBB) by
passive diffusion. It consists of four main parts (Figure 1).
2.2. Generation of Physicochemical and Pharmacological
Parameters. A total of three inputs were required for each
radiotracer: in silico molecular volume and lipophilicity as
represented by McGowan Volume (Vx, cm3/mol/100),
Moriguchi LogP (MLogP, unitless), and an in vitro disso-
ciation constant (KD, nM) (Table 1). Vx and MLogP were
generated based on the chemical structure of the radiotracer
using commercial software, dproperties (Talete, Italy). KD
values were extracted from the literature, measured via
binding assays, using synthetic tau or human brain ho-
mogenates. MLogP was used to derive the free fractions of
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the radiotracer in tissues (fND, unitless) and in plasma (fP,
unitless) from the following relationships [4]:
fND  7.717e−1.634·MLogP,
fP  0.936 · f0.600ND .
(1)
e list of 22 tau radiotracers and their respective in-
puts are shown in Table 1. e KD values that were utilized
for simulations are given in bold for human brain ho-
mogenates, and italicized for synthetic tau, if available for
comparison.
2.3. Derivation of 1TCM Kinetic Parameters. e inux rate
constant (K1, mL/cm3/min) was derived using the modied
Renkin and Crone equation, using compound-specic
permeability (P, cm/min), with xed values of capillary
surface area (S  150 cm2/cm3 of brain) and perfusion (f 
0.6mL/cm3/min) as follows [4, 6]:
K1  f 1− e−PS/f( ). (2)
e compound-specic permeability was derived from
the simplied Lanevskij’s permeability model, with MLogP
and Vx as inputs [4, 6]:
P  10−0.121(MLogP −2.298)2 −2.544log V1/3x( )−2.525. (3)
e eux rate constant (k2, min−1) can be derived using
K1, fP, and fND at equilibrium:
k2 
fND
fP
· K1. (4)
e in vivo nondisplaceable binding potential (BPND,
unitless) was determined using Mintun’s equation with
Bavail, fND, and KD:
BPND  fND ·
Bavail
KD
. (5)
e available tau-binding sites (Bavail, nM) were mea-
sured using enzyme-linked immunosorbent assay (ELISA).
e total amount of tau brils (Bavail, nM) in the frontal
lobes, parietal lobes, and hippocampus in HC and AD were
1.5 and 16.0 nM, respectively [29], assuming a tau molecular
weight of 78,928Da (https://www.phosphosite.org).
2.4. Simulations of Population Time Activity Curves (TACs)
and SUVRs. e predicted K1, k2, and BPND were used to
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Figure 1: Overview of amyloid biomathematical screening methodology.
Computational and Mathematical Methods in Medicine 3
simulate the TACs in the target regions of HC, MCI, and AD
and a reference region, with a fixed arterial input function
(IF):
CTarget(t) � K1 · e
−k2/ 1+BPND( )·t ⊗ IF(t),
CReference(t) � K1 · e
−k2 ·t ⊗ IF(t). (6)
An input function with similar kinetics to that observed
in tau imaging with a fast uptake and washout is required to
reflect tau kinetics. For our simulations, a fixed arterial input
function was applied with fast kinetics that was derived by
averaging the metabolite-corrected arterial plasma input
functions of 6 HC subjects injected with [11C]BF227 [30].
,e same K1 and k2 scaling factors of 1.23 and 1.15, re-
spectively, were introduced to account for the differences
between the predicted and in vivo values [5].,e scaling factor
of BPND was modified from 0.39 to 1.0 because there were few
reported values to determine the appropriate scaling factor.
Monte Carlo simulations were applied to generate 1000 TACs
in both target and reference regions with 3% noise, to reflect
the noise in PETdata, and the population variation, by varying
K1 and k2 by 10% and 20%, respectively [5, 6].,e variations in
the tau fibrils inHC andADwere determined as 10% and 35%,
respectively, using the ratio of the summed standard deviation
to themean value [29].,e amount of soluble tau inHC,MCI,
andADwas reported, but since they did not correlate well with
the amount of phosphorylated tau, these values could not be
used [31]. In our simulations, the total amount of tau fibrils in
MCI was assumed to be the mean of that in HC and AD, with
the same amount of variation of 35%, as used for the amyloid
simulations [5].
1000 noisy TACs in both target and reference regions
were generated by computer simulations with noise. In our
simulation, the target region refers to a brain region with
varying concentrations of phosphorylated tau depending on
subject conditions (e.g., temporal lobe) and a reference is a
brain region devoid of phosphorylated tau (e.g., cerebellum).
1000 SUVRs of each subject condition of HC, MCI, and AD
were determined from the ratio of the areas under the TACs
of the target regions in HC, MCI, and AD and that of the
reference region within a chosen time window. For our
simulations, a default time window of 90–110min was se-
lected as the predicted TACs of HC, MCI, and AD appeared
to reach a quasi-steady-state in this time window for almost
all 9 clinically applied tau radiotracers (Supplementary 2). To
evaluate the efficacy of fixed time windows, SUVRs were also
determined using the literature-reported time windows for
the 9 clinically applied radiotracers.
Table 1: In silico MLogP and Vx and in vitro KD of 22 tau-related PET radiotracers. KD values employed for simulations are given in bold
(measured using brain homogenates) and italicized (measured using synthetic tau).
Radiotracers MLogP Vx KD References for KD
[18F]THK523 3.19 2.11
1.67α [17]
1.99α [18]
86.5 [19]
[18F]THK5105 3.08 2.59 1.45
α
[19]2.63
[18F]THK5116 2.62 2.31 106& [12]
[18F]THK5117 2.85 2.45 2.65$ [20]
[18F]THK5125 3.08 2.59 10.2 [12]
[18F]THK5129 2.48 2.55 3.14 [12]
[18F]THK5151 2.25 2.41 7.07 [12]
[18F]THK5287 1.94 2.55 2.60 [12]
[18F]THK5307 1.71 2.41 5.60 [12]
[18F]THK5317 2.85 2.45 9.40& [21]
[18F]THK5351 2.25 2.41 2.90 [15]
[18F]THK5451 2.25 2.41 28.0 [12]
[18F]flortaucipir 1.95 1.86 14.6# [22]
[18F]T808 3.64 2.23 22.0# [11]
[11C]PBB3 2.34 2.31 2.50
α [10]
6.30 [23]
[18F]FDDNP 2.89 2.31 36.7α [18]
[18F]FPPDB 2.87 3.15 44.8 [24]
[11C]NML 1.98 2.51 0.700α [25]
[18F]Lansoprazol 1.75 2.37 3.30
α [25]
>3998δ [11]
[11C]Astemizole 4.63 3.56
13.4 [26]1.86α>3998δ [11]
[18F]MK6240 2.49 1.96 0.260β [27]
[18F]JNJ64349311 ([18F]JNJ311) 2.07 1.83 7.90δ [28]
Units: MLogP (unitless), Vx (cm3/mol/100), KD (nM). $Averaged KD values (2.2, 3.1) for tau in AD brain homogenates of temporal and hippocampus.
βAveraged KD values 0.14, 0.30, 0.25, 0.24, and 0.38 for tau in AD brain homogenates of frontal and entorhinal cortex of 5 AD. αKD values are measured using
synthetic tau (K18Δ280K) &Ki values measured using AD brain homogenates with THK5105 as competitor δKi values measured using AD brain homogenates
with T808 as competitor. #KD values measured using AD brain via autoradiography.
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2.5. Tracer EvaluationUsing CUI. Az, Es, and Sr are the area
under the receiver operating characteristics curve, effect size,
and SUVR ratios, respectively. ,e 1000 SUVR simulated
under the subject conditions of HC, MCI, and AD were used
to determine Az, Es, and Sr for conditions-pairs of HC-MCI
andMCI-AD. CUI was then derived from the product of the
averaged Az (Az), Es (Es), and Sr (Sr) of conditions-pairs of
HC-MCI and MCI-AD with equal weightage applied:
CUI � Az × Es × Sr. (7)
,e simulated TACs and the predicted SUVR were
compared to the clinical data of 9 clinically applied tau
radiotracers. ,e predicted K1, k2 and BPND values were
compared with the clinically observed values where appli-
cable. Finally, the list of 22 tau radiotracers (Table 1) was
evaluated using CUI. We previously developed a MATLAB-
based program, RSwCUI, (Ver. 2014b, ,eMathWorks, US)
[5], to support the screening of amyloid radiotracers based
on the proposed amyloid biomathematical screening
methodology. ,e program was used for the evaluation of
tau radiotracers in this study.
3. Results
Figure 2 shows the simulated TACs for the target regions of
HC, MCI, and AD and reference regions of 9 clinically
applied tau radiotracers. In general, the clinically observed
TACs of THK compounds of the reference region had higher
peaks and faster washout in the cerebellum than the target
regions [15,32–35], while the peaks of the simulated TACs of
the reference region were always lower than that of the target
regions (Figures 2(a)–2(e)). ,e simulated TACs of [11C]
PBB3 (Figure 2(f )) were close to that observed clinically in
AD in the nonbinding and low-, middle-, and high-binding
regions [10]. ,e simulated TACs of [18F]flortaucipir
(Figure 2(g)) had slightly sharper peaks and faster washout
compared to the clinically observed TACs for both HC and
AD [36]. Unlike the THK compounds, the peaks of the
clinically observed TACs of the target regions of [18F]flor-
taucipir were higher than that of the reference region, which
was also observed in the simulated TACs [36]. ,e predicted
TACs of [18F]T808 for both the reference and the target
regions of HC, MCI, and AD conditions completely over-
lapped with each other (Figure 2(h)). ,e clinically observed
TACs of [18F]T808 appeared close to that of [18F]flortaucipir,
but with smaller differences between the subject conditions.
However, the simulated TACs showed complete overlapped
between the HC and AD conditions with a slower uptake
and washout [37]. ,e predicted TACs of both target and
reference regions of [18F]MK6240 showed similar fast uptake
but slower washout than clinically observed TACs [16].
Table 2 compares the predicted and clinically-reported
values of K1, k2, and BPND of five clinically applied tau
radiotracers with reported kinetic parameters. For [18F]
flortaucipir, the predicted K1 and k2 values of 0.256 and
0.199, respectively, were relatively close to the reported
averaged cerebellar K1 and k2 values of 0.26 and 0.17, re-
spectively [36]. ,e predicted k2 value of [18F]THK5351 was
0.140, which was higher than the clinically observed value of
0.115, with a difference of 21.7% [38]. However, unlike [18F]
flortaucipir where both K1 and k2 values were determined
using the two-tissue-compartment model with a variable
fraction [36], the reported k2 value of [18F]THK5351 was an
apparent rate constant from reference region to plasma,
which was determined using the simplified reference tissue
model (SRTM) [38].
,e predicted k2 value of [18F]THK5317 of 0.087 was
close to the literature-reported value of 0.09, even though
K1 of [18F]THK5317 value differed of [18F]THK5317 from
the clinically observed value with a difference of −39% [39].
,e predicted BPND values of 0.125 and 8.13 were very
different from the clinically observed values of 0.60 and
5.11 in AD for [18F]THK5317 [39] and [18F]MK6240 [16].
,e predicted BPND value was fairly close to that of [11C]
PBB3 [10]. ,e predicted K1 of [18F]MK6240 was close to
the clinically observed K1 value with 2.50% difference but
the predicted k2 value yielded greater difference of about
40% [16].
Table 3 shows the predicted SUVR values obtained using
the default time window and literature-reported time
window of 90–110min, and the clinically observed SUVR for
10, 10, and 9 clinically applied tau radiotracers. ,e dif-
ferences in the SUVRs predicted using both time windows
were very small for both HC and AD. ,e predicted SUVR
for HC was always greater than 1.0, but the clinically ob-
served SUVR values were less than 1.0 for some radiotracers.
In general, the clinically observed SUVR for HC and AD
were greater than the predicted SUVR determined using the
literature-reported time window, except for [11C]PBB3 and
[18F]MK6240, where the predicted SUVR for HC and AD
were greater.
,e correlations between the predicted and highest
clinically observed SUVR for AD were similar with co-
efficients of determination, R2 of 0.90 and 0.89, re-
spectively, using the literature-reported time window
and the default time window (Figure 3). However, the
good correlation was driven by [18F]MK6240, which had
the highest predicted and clinically observed SUVR. Poor
correlation was observed after removing [18F]THK5351
and [18F]MK6240. ,e small difference between the
predicted SUVR using the default and clinical-reported
time window, and the value of R2, showed that the default
time window of 90–110min was suitable for predicting
the SUVR of the tau radiotracers (Figure 3).
,e simulated SUVR distribution of [18F]THK523
across HC, MCI, and AD conditions substantially
overlapped each other (Figure 4(a)). However, the
clinically observed SUVR distribution of [18F]THK523
differed across different regions of interest, with HC−
(PIB-negative) having the smallest spread and smallest
values, HC+ (PIB-positive) having a relatively large
spread and values ranging between that of HC− and AD,
and AD subjects having the largest values and a nearly
similar spread as HC+ [30]. For [11C]PBB3, [18F]
THK5117, and [18F]flortaucipir, the clinically observed
SUVR distributions were generally larger for AD than
HC for all regions of interest analyzed, in terms of the
spread and absolute values [14, 34, 40]. ,e trend of the
Computational and Mathematical Methods in Medicine 5
simulated SUVR population distribution was close to
that observed clinically for HC and AD conditions
(Figures 4(b)–4(d)). is supported the use of 35%, 35%
and 10% variations in Bavail for population simulations.
Figure 5 shows the CUI distribution of 22 tau-related
radiotracers. Among the clinically applied tau radiotracers,
[18F]MK6240 was ranked rst, followed by [18F]THK5351,
[18F]THK5117, [11C]PBB3, [18F]ortaucipir, [18F]THK5317,
[18F]FDDNP, [18F]T808, and [18F]THK523, based on the KD
values measured using AD brain homogenates. For candi-
date radiotracers, [18F]THK5287 was ranked rst based on
the KD values measured using AD brain homogenates, while
[11C]NML was ranked rst based on the KD values measured
using heparin-induced tau polymer (HITP) (Table 1). e
CUI values generated using the KD values for the synthetic
tau were higher than those of the brain homogenates as the
KD values measured using synthetic tau were smaller (Ta-
ble 1). e ranking of the CUI values generated using the KD
values measured with synthetic tau and brain homogenates
di¦ered for [18F]THK523, [18F]THK5105, and [11C]PBB3. 10
out of 16 tau radiotracers had CUI values higher than the
recommend CUI value of 3.0, where the results were simu-
lated using KD values measured with human brain homog-
enates. Apart from [18F]THK523, [18F]THK5317, [18F]T808,
and [18F]FDDNP, the other 6 clinically applied tau radio-
tracers yielded high CUI values. e CUI values ranged from
about 0.0 to 16.2, which ranged wider than that for amyloid.
4. Discussion
In this paper, we evaluated the feasibility of extending a
previously developed amyloid biomathematical screening
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Figure 2: Simulated TACs of target regions of HC, MCI, and AD and reference regions for (a) [18F]THK523, (b) [18F]THK5105, (c) [18F]
THK5117, (d) [18F]THK5317, (e) [18F]THK5351, (f ) [11C]PBB3, (g) [18F]ortaucipir, (h) [18F]T808, and (i) [18F]MK6240 from 0–120min.
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methodology to support the screening of candidate tau
radiotracers during compound development. 22 clinically
applied and candidate tau-related radiotracers were thus
used to investigate the CUI ranking of clinically applied and
candidate tau radiotracers.
4.1. Comparison of Simulated TACs and SUVR Distribution.
,e simulated TACs were very different from the clinically
observed TACs of [18F]THK523 and [18F]T808, but were
only slightly different for that of [18F]THK5117, [18F]
THK5351, [18F]flortaucipir, [11C]PBB3, and [18F]MK6240
(Figure 2). ,e simulated SUVR distributions were different
for [18F]THK523 but were similar to the clinically observed
results under HC and AD conditions for [18F]THK5117,
[18F]flortaucipir, and [11C]PBB3 (Figure 4). Both the pre-
dicted and clinically observed SUVR values were less than
1.0 in HC for some radioligands, especially those with a
lower selectivity for tau (e.g., [18F]THK523). ,e clinically
observed SUVR of AD is much higher than that of HC.
However, there is little difference in the predicted SUVR for
[18F]THK523. ,is shows that the predictions were less
accurate for tau compounds with a lower selectivity for the
target. Poor predictions might be due to binding to other
β-sheet structured proteins or off-target sites shown in the
clinical data, whereas the predicted values showed the
binding of the radiotracers to only the target site. Non-
specific binding in white matter may also lead to spill-over
into the surrounding cortical regions, leading to higher
clinically observed SUVRs.,e issue of non-specific binding
Table 2: Comparison of predicted and clinically observed K1, k2, and BPND values of four clinically applied tau radiotracers.
Radiotracers
Literature
Predicted
values
%
diffParameters Region Clinically observedvalues References
[18F]flortaucipir K1
Cerebellum excluding
vermis 0.26 [36] 0.256 −1.54
k2 0.17 0.199 17.1
[18F]THK5351 (S-enantiomer of [18F]
THK5151) k2′‡ Targetβ 0.115 [38] 0.140 21.7
[18F]THK5317 (S-enantiomer of [18F]
THK5117)
K1 Targetδ 0.33 [35] 0.202 −38.8k2 0.09 0.087 −3.33
BPND
(AD)∗ Putamen 0.60 [39] 0.125 −79.2
[11C]PBB3 BPND(AD)¶
High-binding cortical
regions 0.37 [10] 0.427 15.4
[18F]MK6240
K1 Posterior cingulate
cortex
0.246
[16]
0.252 2.50
k2 0.099 0.138 39.2
BPND§ 5.11 8.13 59.2
βTarget ROIs: anterior cingulate, brainstem, caudate nucleus, eroded white matter, entorhinal cortex, frontal cortex, fusiform gyrus, hippocampus, inferior
temporal cortex, lingual gyrus, middle temporal gyrus, occipital cortex, pallidum, parahippocampal gyrus, parietal cortex, posterior cingulate, precuneus,
putamen, thalamus. δTarget ROIs: thalamus, putamen, hippocampus, amygdala, parietal cortex, frontal cortex, sensory motor cortex, occipital cortex,
midbrain, entorhinal cortex, and temporal cortex. ∗BPND � DVR-1, where DVR was determined using reference Logan, averaged from 4 prodromal AD.
¶BPND determined using MRTM0. §BPND determined using k3/k4 using 2T4CM in 7 symptomatic individuals classified as MCI and AD. ‡k2′ optimized from
fitting all target ROIs using SRTM with cerebellum as the reference region.
Table 3: Comparison of predicted (literature-reported and default time window of 90–110min) and clinically observed SUVR (highest
SUVR in AD) of HC and AD conditions.
Clinically applied radiotracers
Predicted SUVR Clinically observed SUVR
Default Literature Highest inAD Regions Time window (min) References
HC AD HC AD HC AD
[18F]THK523 1.00 1.01 1.00 1.01 0.96 1.81 ITL 60–90 [32]
[18F]THK5105 1.03 1.34 1.03 1.35 1.41 1.52 PU 90–100 [33]
[18F]THK5117 1.04 1.47 1.05 1.56 1.57 1.77 PU 50–60 [34]
[18F]THK5317 1.01 1.13 1.01 1.14 — — — — —
[18F]THK5351 1.10 2.11 1.11 2.38 2.14 2.98 HIP 50–60 [15]
[18F]flortaucipir 1.03 1.35 1.03 1.35 1.17 2.19 ITL 80–100 [40]
[18F]T808 1.00 1.02 1.00 1.02 0.94 1.52 LTL 80–100 [35]
[11C]PBB3 1.04 1.43 1.05 1.55 0.85 1.42 Global# 30–50 [10]
[18F]FDDNP 1.00 1.03 1.00 1.04 1.24 1.37 ACG 45–55 [41]
[18F]MK6240 1.78 9.94 1.78 9.93 — ∼5∗ PRE 90–110 [16]
ITL � inferior temporal lobe, LTL � lateral temporal lobe, PU � putamen, PAR � parietal lobe, HIP � hippocampus, ACG � anterior posterior cingulate, PRE
� precuneus. #Global � cerebral cortex for HC and high binding ROI for AD. ∗SUVR is approximated from the plot, taking the highest SUVR in AD.
Computational and Mathematical Methods in Medicine 7
is more apparent for tau radiotracers with lower tau-binding
selectivity, such as [18F]THK523 and [18F]THK5117
(Table 2).
4.2. Comparison of Predicted 1TCM and SUVR. e pre-
diction for the K1 and k2 values of the tau radiotracers
appeared to work well in racemic compounds (e.g., [18F]
ortaucipir), but not as well for enantiomeric compounds
like [18F]THK5351 and [18F]THK5317, which are
S-enantiomers of [18F]THK5151 and [18F]THK5117 re-
spectively (Table 2).e predictions for BPND were generally
poor for the three clinically-reported tau radiotracers (Ta-
ble 2). is may be due to the use of a simplied 1TCM for
prediction, even though 2TCM was reported to be more
suitable for many clinically applied tau radiotracers. e
simplied 1TCM was selected even though 2TCM is more
accurate for modeling tau kinetics as the prediction of a
larger number of microparameters may be di§cult to es-
timate reliably. Moreover, the 1TCM worked reasonably
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Figure 4: Simulated SUVR distributions of (a) [18F]THK523, (b) [18F]THK5117, (c) [18F]ortaucipir, (d) [11C]PBB3.
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well in predicting the kinetics of the amyloid radiotracers,
even though 2TCM was reported to be more suitable [5].
Other possible reasons for the poorer BPND predictions in-
cluded di¦erences in binding to the plasma proteins due to
the enantiomeric properties of the radiotracers [42], me-
tabolites crossing the BBB for [11C]PBB3 [10], binding of tau
radiotracers to other similar β-sheet structures (Aβ and α--
synuclein), or o¦-target binding in target regions of interest
[13–15]. e predicted 1TCM parameters and SUVR, as well
as the simulated TACs and SUVR distribution, were com-
pared to clinically observed data where applicable. However,
we were limited by the small number of reported kinetic
parameters and SUVR values to fully assess the amyloid
biomathematical model for screening tau radiotracers.
e predicted and highest clinicallyobserved SUVR data
for AD correlated well using xed time window of 90–
110min and the literature-reported time window with R2
values of 0.88 and 0.89 respectively, for 9 clinically applied
tau radiotracers (Figure 3). However, the results were driven
mostly by [18F]MK6240. Some of the clinically applied tau
radiotracers ([18F]THK523, [18F]THK5351 and [18F]or-
taucipir) did not have high selectivity for tau, which may
have contributed to smaller predicted values as the predicted
values were based on binding to a single target site but the
o¦-target binding or specic binding to other β-sheet
structures (e.g., amyloid) may yield higher clinical SUVR
values. e predicted TACs of [18F]T808 exhibited a much
slower clearance compared to the clinically observed ki-
netics, which resulted in a large di¦erence between the
predicted and clinically observed SUVR. is may be due to
the poor predictive ability of in silico parameters for [18F]
T808, which has a unique chemical structure.
4.3. Comparison of Tau Radiotracers with CUI. e CUI
value of [18F]ortaucipir was large while the CUI value of
[18F]T808 was very small and does not appear to be a
promising clinical tau radiotracer. Similarly, [18F]THK523
also yielded a small CUI value, even though studies showed
that it could be applied clinically. [18F]THK523, [18F]Lan-
soprazole, and [11C]Astemizole yielded small CUI values
using the KD values measured using human brain homog-
enates, which di¦ered greatly from that measured using
synthetic tau. KD or Ki values measured using AD brain
homogenates were very di¦erent from those measured using
heparin-induced tau polymer (HITP) (Table 1). is is
because HITP is composed of only 3R and/or 4R, and hence
may not undergo the same phosphorylation process as
human tau [19, 43]. On the other hand, theKD orKi values of
amyloid radiotracers measured using synthetic tau and AD
brain homogenates did not di¦er greatly [5]. e huge
di¦erence in the KD values measured using human brain
homogenates and synthetic tau were much greater for [18F]
THK523 than for [18F]THK5105 (Table 1). is might also
indicate the binding preferences of [18F]THK523 to certain
tau-binding sites available on synthetic tau, that were fewer
in numbers in human brain homogenates. erefore, it is
important to determine the binding a§nity of tau radio-
tracers to di¦erent subtypes of tau protein and other β-sheet
structures such as Aβ and α-synuclein.
[18F]THK5351 yielded higher clinically observed SUVR
than [18F]THK5117 in the same AD patients, with lower
white matter binding [15]. [18F]THK5351 was also reported
to have a higher signal-to-noise ratio (SNR), and a lower
non-specic binding in white matter than [18F]THK5105
and [18F]THK5117 [8]. Similarly, the CUI value of [18F]
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Figure 5: CUI distributions of 22 tau-related PET radiotracers.
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THK5351 was higher than [18F]THK5105 and [18F]
THK5117. [11C]PBB3, [18F]flortaucipir, and [18F]THK5105
have nearly similar CUI values (Figure 5), but the difference
in the clinically observed SUVR values between HC and AD
were greatest in [18F]flortaucipir, followed by [11C]PBB3
then [18F]THK5105 (Table 3). ,is difference may be at-
tributed to the tau subtypes that [11C]PBB3 is binding. [18F]
THK5351 and [18F]flortaucipir was reported to bind to the
same targets but with different affinities, while [11C]PBB3
seems to bind to a different tau subtype [44]. If the tau
subtype that [11C]PBB3 binds to is of a lower concentration
in subject, the clinical SUVR will become smaller. ,e
difference between the clinically observed results and CUI
ranking showed that the evaluation of the clinical usefulness
of tau radiotracer based on binding to a single target could
not reflect the actual in vivo binding in subjects. High tau
selectivity and off-target binding affect the comparison of the
in vivo binding of tau radiotracers, which are less prominent
in amyloid radiotracers. Despite the differences in CUI
rankings, the clinically applied tau radiotracers had CUI
values above the recommended value especially for those
with high SNR. ,us, the screening methodology can still
provide confidence in the decision-making of moving
candidate radiotracers for clinical studies.
4.4. Limitations of Screening Methodology. Few measure-
ments of tau concentration in postmortem human brains
using ELISA have been reported, and these values are very
different [17, 29, 45, 46]. In addition, these reported tau
concentrations were mostly measured using normal-aged
control and AD brains, with very little data on the tau
concentration in MCI. As such, the simulated SUVR dis-
tribution might not reflect the clinically observed MCI re-
sult. Moreover, the input function of the amyloid radiotracer
[11C]BF227 was used for simulations. ,us far, the input
functions of only three clinically applied tau radiotracers of
[11C]PBB3 [10], [18F]flortaucipir [36], and [18F]MK6240 [16]
have been reported. ,e arterial input functions of these
radiotracers were similar in HC and AD, with a fast uptake
and a fast washout, and the shape of the curves was similar to
that of [11C]BF227 as used in the simulation. Although the
shape of the input function of these two radiotracers was
similar to that of [11C]BF227, the shape of the arterial input
function might be different for other tau radiotracers. ,us,
we evaluated the effect of the input function on the outcome
using four different input functions with fast kinetics for HC
and AD subjects injected with [11C]BF227 or [18F]FACT,
with areas under the input function curves from 0 to 120min
of 536 (default), 649, 434, and 306 (kBq/mL) min. ,e %
COV of the predicted SUVR was less than 7.0 for all con-
ditions and radiotracers, while %COV of the CUI was less
than 7.0 for all except the poor radiotracers, namely, [18F]
FDDNP, [18F]FPPDB, and [11C]Astemizole. ,is showed
that the results would not be changed significantly using
input functions with similar kinetics. However, there were
also issues with metabolites crossing the BBB (e.g., [11C]
PBB3), but the amyloid biomathematical screening
methodology could not be used to predict the possibility of
metabolites crossing this barrier.
Off-target binding was observed in some clinically ap-
plied tau radiotracers. [18F]flortaucipir was reported to show
specific binding in the midbrain, vessels, iron-associated
regions (e.g., basal ganglia), substantia nigra, calcifications
in the choroid plexus, and leptomeningeal melanin [13].
[11C]PBB3was reported to accumulate in the venous sinuses,
basal ganglia, and thalamus, while its fluorinated com-
pounds showed off-target binding in the choroid plexus
[14, 44]. [18F]THK5351 was reported to bind to monoamine
oxidase B (MAO-B), which is highly expressed throughout
the brain, and thus, its tau binding data needs to be corrected
for MAO-B binding [47]. [18F]MK6240 was reported to have
reduced off-target binding on the whole but showed off-
target binging in regions such as the retina, substantia nigra,
ethmoid sinus, and dura matter [16]. Depending on the
region of off-target binding, the effects may not limit PET
quantification due to little or no anatomical overlap of the
target regions of interest (ROIs) with off-target regions.
Accurate PET quantification is also less affected if the ra-
diotracer has high target selectivity or if the concentrations
of the off-target binding sites are much lower compared to
that of the target [48]. Off-target binding may be one of the
contributing factors that led to the observed differences
between simulation and the clinical data of tau PET ra-
diotracers. ,e possibility of binding to off-targets is difficult
to predict, and systematic screening is required to determine
the binding of the candidate compound to a wide range of
proteins. ,is will increase the time and cost of compound
screening. ,e amyloid biomathematical screening meth-
odology could not predict off-target binding, and the in-
clusion of multiple binding sites appeared to be required for
tau radiotracers to correct for this issue.
4.5. Feasibility of Extending to the Screening of Tau
Radiotracers. To date, the comparison of multiple tau ra-
diotracers has been performed via in vitro competition
binding assays in human brain sections, using human AD
brain homogenates [11, 12] or by means of preclinical
imaging [38]. ,ere is a lack of consideration of the possible
in vivo kinetics of the radiotracers during development,
which may lead to poor clinical performance [4–6]. ,e use
of in silico data can support predictions of tracer kinetics and
increases confidence in clinical translation, in addition to
facilitating radiotracer comparisons. ,e weak SUVR cor-
relation was obtained between the predicted and clinically
observed SUVR results, mostly due to the small SUVR values
for tau radiotracers with poorer tau selectivity. However,
there are very few reported kinetic parameters to assess the
limitations of the screening methodology. ,e TACs, SUVR
distribution, and CUI rankings differed primarily for tau
radiotracers with low selectivity to tau. ,is showed that the
evaluation of the clinical usefulness of tau radiotracer based
on binding to a single target could not fully reflect the actual
in vivo binding in subjects since they also exhibited binding
preferences to nontarget sites. ,us, it is not feasible to
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directly apply the amyloid biomathematical screening
methodology to tau radiotracers due to the increased
complexity of evaluating the binding of tau radiotracers,
namely, target-binding, off-target binding, and non-specific
binding. More work is required to improve the accuracy of
predicting the clinical usefulness of tau radiotracers by in-
cluding possible binding to other β-sheet structures or off-
target sites. However, the high CUI values generated for
clinically applied tau radiotracers with high SNR showed
that the screening methodology could be used to increase
confidence in decision-making when choosing candidate
radiotracers for further evaluation.
5. Conclusions
,e predicted TACs, SUVR, and CUI ranking differed for
some clinically applied tau radiotracers, especially those
with lower selectivity for tau. ,is showed that the eval-
uation of the clinical usefulness of tau radiotracer based on
binding to a single target could not reflect the actual in vivo
tau binding in subjects due to more challenges in evaluating
the in vivo binding of tau radiotracers, such as off-target
binding and high tau selectivity, compared to amyloid
radiotracers. ,e inclusion of possible binding to other
β-sheet structures or off-target sites and the binding af-
finities to different target sites would improve the accuracy
of the prediction. From our results, clinically applied tau
radiotracers with higher SNR, such as [18F]MK6240 and
[18F]THK5351, had higher CUI rankings. ,is supported
the use of the screening methodology in radiotracer de-
velopment by allowing comparison of candidate radio-
tracers with clinically-applied radiotracers based on SUVR,
with respect to binding to a single target. Our results will
hopefully provide some insights to guide the development
of in silico models in supporting the development of tau
radiotracers.
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